Adamax
Also called Semax-related ACTH analogue
A research-product name marketed as a Semax-related nootropic. Published Semax experiments do not show that Adamax improves focus, memory or brain health, and direct Adamax research is scarce.
Overview
What it is
A compound sold as a modified relative of Semax, an ACTH-derived peptide. The trade name alone does not confirm the full sequence or modifications, so batch documentation matters.
How it works
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) changed levels of BDNF, a nerve-growth protein, and its receptor TrkB in rat brain studies. Those papers did not test Adamax, and a change in one rat brain protein is not an improvement in human daily function.
What the research shows
No controlled Adamax clinical trial was identified. A 2025 New Zealand Medsafe regulatory proposal named Adamax and Semax among ACTH analogues marketed for cognitive enhancement and noted limited clinical research and uncertainty about long-term effects.
Studied for
- Semax effects on BDNF in ratsnot Adamax
- Focus, memory and mood claimsnot established
Safety and regulatory status
Safety and side effects
No Adamax-specific side-effect rate, long-term safety or interaction profile exists. Ongoing problems with concentration, memory or mood deserve clinical evaluation.
Regulatory status
Not approved by the FDA. Regulators in some countries are reviewing how ACTH analogues sold as nootropics should be classified.
Mixing and dosing reference
Reference information only. Read before using this section.
Adamax (10 mg Vial) Dosage Protocol
- Vial
- 10 mg Adamax
- Add diluent
- 3 mL
- Concentration
- 3.33 mg/mL
- 1 unit (U-100)
- 33.33 mcg in 0.01 mL
- Route
- Subcutaneous
- How often
- Once per day (subcutaneous), preferably morning for consistency.
- Typical range
- 500–1000 mcg once daily (gradual titration).
- Cycle length
- 8–12 weeks; optional extension to 16 weeks with careful monitoring.
Standard / Gradual Approach
| Week | Daily Dose | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 300 mcg (0.3 mg) | 9 units (0.09 mL) |
| Weeks 3–4 | 500 mcg (0.5 mg) | 15 units (0.15 mL) |
| Weeks 5–6 | 750 mcg (0.75 mg) | 23 units (0.23 mL) |
| Weeks 7–8 | 1000 mcg (1.0 mg) | 30 units (0.30 mL) |
How to mix
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall to avoid foaming.
- Gently swirl or roll the vial until powder fully dissolves (do not shake vigorously).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Dosing details
- Start: 300 mcg daily for 2 weeks (Week 1–2); allows adaptation to peptide effects.
- Increase: 500 mcg daily (Week 3–4), then 750 mcg (Week 5–6).
- Maintenance: 1000 mcg daily (Week 7+) for continued nootropic support.
- Frequency: Once per day (subcutaneous), preferably morning for consistency.
- Cycle Length: 8–12 weeks; optional extension to 16 weeks with careful monitoring.
- Off‑Cycle: Equal duration break (e.g., 8 weeks on, 8 weeks off) to prevent tolerance.
Storage
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; keep in original packaging to minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); follow the exact preparation’s validated use-by and sterile-handling instructions.
- Avoid Freeze–Thaw: Do not refreeze reconstituted solution; freeze–thaw cycles denature peptides.
- Allow lyophilized vials to reach room temperature before opening to reduce condensation.
Administration technique
- Clean the vial stopper with an alcohol swab and allow to dry (~10 seconds).
- Draw the calculated dose into a sterile insulin syringe; remove air bubbles by gently tapping the syringe.
- Clean the injection site (abdomen, thigh, or upper arm) with a fresh alcohol swab; allow to dry.
- Pinch a fold of skin (~1 inch) between thumb and forefinger to elevate subcutaneous tissue.
- Insert the needle at 45–90° into the skinfold; inject slowly and steadily (do not aspirate).
- Withdraw the needle and apply gentle pressure with a clean gauze pad; do not massage the site aggressively.
- Rotate injection sites systematically to prevent lipohypertrophy and ensure consistent absorption.
Important notes
- Use new sterile insulin syringes for each injection; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) daily to reduce local irritation and lipohypertrophy.
- Inject slowly and steadily; wait a few seconds before withdrawing the needle to prevent leakage.
- Document daily dose, injection site, and any subjective effects (cognition, mood, sleep) to track response.
- For doses under 10 units (Week 1–2: 9 units), consider 30‑ or 50‑unit insulin syringes for better precision.
Protocol source: PeptideDosages.com
Common questions
Is Adamax the same as Semax?
Do not assume so. Their relationship does not establish identical chemistry or effects.
Is Adamax stronger than Semax?
That would require a direct comparison, which has not been published.
Does high purity prove it works?
No. Purity, identity, safety and effectiveness are separate questions.
Related in Brain and Cognitive Health
Sources and further reading (4)
- Medsafe. Peptide group-classification proposal, ACTH-analogue section, 2025.
- Dolotov OV, et al. Semax and BDNF/TrkB expression in the rat hippocampus. Brain Research, 2006.
- Dolotov OV, et al. Semax binding and BDNF in the rat basal forebrain. J Neurochem, 2006.
- Source summary: PeptideDosages.com research overview (rewritten for NVO).